PE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its pr...
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.